NO20055835L - Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents

Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Info

Publication number
NO20055835L
NO20055835L NO20055835A NO20055835A NO20055835L NO 20055835 L NO20055835 L NO 20055835L NO 20055835 A NO20055835 A NO 20055835A NO 20055835 A NO20055835 A NO 20055835A NO 20055835 L NO20055835 L NO 20055835L
Authority
NO
Norway
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
cyclic amine
Prior art date
Application number
NO20055835A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055835D0 (no
Inventor
Aldo Feriani
Giuseppe Alvaro
Riccardo Giovannini
Catia Seri
Luca Arista
Francesca Cardullo
Adamo Lucilla D
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20055835D0 publication Critical patent/NO20055835D0/no
Publication of NO20055835L publication Critical patent/NO20055835L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055835A 2003-05-09 2005-12-08 Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem NO20055835L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310724.0A GB0310724D0 (en) 2003-05-09 2003-05-09 Chemical compounds
PCT/EP2004/005005 WO2004099143A1 (en) 2003-05-09 2004-05-07 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20055835D0 NO20055835D0 (no) 2005-12-08
NO20055835L true NO20055835L (no) 2006-02-07

Family

ID=9957781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055835A NO20055835L (no) 2003-05-09 2005-12-08 Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Country Status (21)

Country Link
US (2) US20070073061A1 (pt)
EP (1) EP1622871A1 (pt)
JP (1) JP4684221B2 (pt)
KR (1) KR20060009313A (pt)
CN (1) CN100534983C (pt)
AR (1) AR044269A1 (pt)
AU (1) AU2004235967B2 (pt)
BR (1) BRPI0410154A (pt)
CA (1) CA2524894A1 (pt)
EG (1) EG24668A (pt)
GB (1) GB0310724D0 (pt)
IS (1) IS8164A (pt)
MA (1) MA27795A1 (pt)
MX (1) MXPA05012096A (pt)
MY (1) MY140027A (pt)
NO (1) NO20055835L (pt)
NZ (1) NZ543068A (pt)
RU (1) RU2392270C2 (pt)
TW (1) TWI332499B (pt)
WO (1) WO2004099143A1 (pt)
ZA (1) ZA200508339B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7844037B2 (en) 2005-08-08 2010-11-30 Palm, Inc. Method and device for enabling message responses to incoming phone calls
US8067447B2 (en) 2006-11-01 2011-11-29 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MX2011001846A (es) * 2008-09-01 2011-04-04 Neurosearch As Nuevos derivados de piperidina-4-acetamida y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
CN106187999A (zh) * 2015-05-04 2016-12-07 复旦大学 取代哌啶类化合物及其制备方法和用途
BR112023019211A2 (pt) 2021-03-23 2023-11-28 Bioage Labs Inc Inibidores de inflamassoma nlrp3
US11787805B2 (en) 2022-01-28 2023-10-17 BioAge Labs, Inc. N-oxide inhibitors of NLRP3 inflammasome
TW202547472A (zh) 2024-03-26 2025-12-16 美商百愛及生物醫藥公司 Nlrp3發炎體之抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309720A (en) * 1884-12-23 William p
NL262366A (pt) * 1960-03-14
GB1356117A (en) * 1970-12-16 1974-06-12 Searle & Co 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
DE19603767A1 (de) * 1996-02-02 1997-08-07 Hoechst Ag Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
AU1415099A (en) * 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
ATE460163T1 (de) * 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
AR037429A1 (es) * 2001-11-26 2004-11-10 Schering Corp Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20060128752A1 (en) * 2002-07-03 2006-06-15 Giuseppe Alvaro Chemical compounds

Also Published As

Publication number Publication date
US20090192194A1 (en) 2009-07-30
US20070073061A1 (en) 2007-03-29
RU2005138315A (ru) 2007-06-20
JP4684221B2 (ja) 2011-05-18
BRPI0410154A (pt) 2006-05-16
IS8164A (is) 2005-12-01
MA27795A1 (fr) 2006-03-01
EP1622871A1 (en) 2006-02-08
TW200510309A (en) 2005-03-16
NO20055835D0 (no) 2005-12-08
KR20060009313A (ko) 2006-01-31
MXPA05012096A (es) 2006-02-08
WO2004099143A1 (en) 2004-11-18
AU2004235967B2 (en) 2008-10-23
MY140027A (en) 2009-11-30
TWI332499B (en) 2010-11-01
RU2392270C2 (ru) 2010-06-20
EG24668A (en) 2010-04-11
AU2004235967A1 (en) 2004-11-18
AR044269A1 (es) 2005-09-07
GB0310724D0 (en) 2003-06-11
CN1819995A (zh) 2006-08-16
ZA200508339B (en) 2006-10-25
CN100534983C (zh) 2009-09-02
NZ543068A (en) 2009-07-31
JP2006525975A (ja) 2006-11-16
CA2524894A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
NO20042155L (no) N-adamantylmetylderivater og mellomprodukter som farmasoytiske sammensetninger og fremgangsmater til deres fremstilling
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20023643L (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2083007T3 (da) Tiotropiumsalte, fremgangsmåder til deres fremstilling og lægemiddelformuleringer indeholdende disse
NO20055835D0 (no) Cykliske aminderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
NO20043188L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20031219L (no) Nye forbindelser avledet fra kinazolin, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DK2067779T3 (da) Tiotropiumsalte, fremgangsmåde til deres fremstilling og lægemiddelformuleringer indeholdende disse
NO20031643L (no) Nye aminotriazolonforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DK1707564T3 (da) Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1742927T3 (da) Butanonsyrederivater, fremgangsmåder til fremstilling deraf, farmaceutiske præparater omfattende dem, og farmaceutiske applikationer deraf
NO20055167D0 (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20034614L (no) Nye [3,4-a:3,4-c]karbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20041313L (no) Nye isokinolinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20035215L (no) Tricykliske dihydrokinolinforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO20052414L (no) Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1150970T3 (da) (1-phenacy-3-phenyl-3-piperidylethyl)piperidin-derivater, fremgangsmåde til deres fremstilling og farmaceutiske sammensætningner indeholdende dem
NO20043910L (no) Nye aminosyreforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem